Amalgamation of Gujarat Themis Biosyn with Themis Medicare

The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL

Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity

Construction of the plant will commence in 2025 with first production expected to be in 2027

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

Shilpa Medicare receives USFDA approval for Bortezomib injection

Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Themis Medicare posts Q1 FY25 consolidated PAT higher at Rs. 24.68 Cr

Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024

Merck Life Science inks MoU with ICAR-CIFT, Kochi for research in fishing process